Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial
Max Schreuer(Universitair Ziekenhuis Brussel), Yanina Jansen(Universitair Ziekenhuis Brussel), Simon Planken(Universitair Ziekenhuis Brussel), Inès Chevolet(Ghent University Hospital), Teofila Seremet(Universitair Ziekenhuis Brussel), Vibeke Krüse(Ghent University Hospital), Bart Neyns(Universitair Ziekenhuis Brussel)
Cited by 184
Abstract
Related Papers
No related papers found
Powered by citation graph analysis